Stevens First Principles Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-700	Closed	-$357K	–	228
2015 Q2	$357K	Buy	700 +300	+75%	+$146K	0.23%	68
2015 Q1	$181K	Buy	400 +200	+100%	+$84.8K	0.12%	82
2014 Q4	$82K	Sell	200 -10	-5%	-$3.93K	0.05%	115
2014 Q3	$76K	Buy	+210	New	+$70.4K	0.04%	131
2014 Q2	–	Sell	-250	Closed	-$75K	–	229
2014 Q1	$75K	Buy	+250	New	+$77K	0.05%	124

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Stevens First Principles Investment Advisors's REGN Position: Q3 2015 in Review

Stevens First Principles Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 700 shares — an estimated $357K sold.

Stevens First Principles Investment Advisors first reported a position in REGN in Q1 2014 and held it in 5 quarters. The position peaked at $357K in Q2 2015. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

Stevens First Principles Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 700 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $357K.
Stevens First Principles Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Stevens First Principles Investment Advisors's Regeneron Pharmaceuticals position peaked at $357K in Q2 2015.
563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.